Form D · Biotechnology

Organogenesis Holdings Inc.

Canton, MA · CIK 0001661181

Offering snapshot reported Nov 27, 2024 · SEC filing

Reported sold
$130M
Offering amount: $130M
Investors reported
2
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Nov 12, 2024
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Nov 27, 2024Initial$130,000,000No comparison2SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$5.2M
Finders' fees
$0
Form D file number
021-530682

Sales compensation recipients

Scroll to see all columns →

RecipientCRDAssociated broker-dealer
Truist Securities, Inc.6271

Source: Form D, filed Nov 27, 2024. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Ades Director
Alan A. Ades Director
Patrick Bilbo Executive
Robert Cavorsi Executive
Michael J. Driscoll Director
Prathyusha Duraibabu Director
David Erani Director
David C. Francisco Executive
Lori Freedman Executive
Jon Giacomin Director
Gary S. Gillheeney, Sr. Director, Executive
Brian Grow Executive
Michele Korfin Director
Arthur S. Leibowitz Director
Garrett Lustig Director
Antonio Montecalvo Executive
Glenn H. Nussdorf Director
Gilberto Quintero Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
85 Dan Road
Canton, MA, 02021